• Selection of news and upcoming events

Eleusis sheds light on psychedelics that relieve asthma in rats with no mental effects

Psychedelic drugs like LSD have long been of interest in the medical community because of their anti-inflammatory properties. But efforts to transform them into therapeutics have been hampered by laws restricting the use of psychedelics, not to mention the stigma associated with them.

Eleusis was founded in 2014 with the mission of turning psychedelics into anti-inflammatories, and now it has data from preclinical study that it will use to guide the development of its first drug candidates to treat inflammatory conditions.

The company’s researchers screened 21 psychedelics that target the serotonin receptor 5-HT2A. Activating the receptor is known to have anti-inflammatory effects in asthma. The team discovered that the structural characteristics of one class of psychedelics known as 2,5-dimethoxyphenethylamine (2C-H) allow them to control inflammation without producing the behavioral effects of LSD and related drugs. They published their observations in the journal ACS Pharmacology & Translational Science.

Please, to access the full article visit Fierce Biotech